Radioimmunoassay/Biomarkers Core

放射免疫分析和生物标志物核心建议继续提供越来越多的高 为我们不断发展的糖尿病研究中心（DRC）提供高质量的免疫分析服务， 临床科学家。上一个周期的服务包括放射免疫测定、酶联免疫测定、放射免疫分析和放射免疫分析。 免疫吸附测定（ELISA）和Luminex平台上的多重ELISA，用于扩大各种 糖尿病和代谢相关的激素和细胞因子来源于血液、尿液和组织样品。 这些检测服务已被证明对DRC和宾夕法尼亚大学糖尿病研究所当前的研究至关重要， 肥胖和代谢（IDOM），并将继续成为未来运营和发展的一个组成部分， 中心和研究所。在下一个周期，RIA/生物标志物核心将扩大其现有服务， 在基于数字ELISA（Simoa）的更灵敏的多重平台上开发测定。Simoa 技术将被用来开发一种新的胰高血糖素ELISA必要的低样本量胰岛研究， 啮齿动物和灌流实验中，并实现细胞因子的精确多重1000倍 提高了了解啮齿动物炎症和代谢交叉点所需的灵敏度， 人体研究，从而提高DRC研究人员的分析服务价值。此外，核心将 积极参与当地糖尿病、肥胖和代谢研究社区的外联活动 研究人员，同时加强所提供的分析服务的QA/QC/QM。此外，RIA/生物标志物 核心将整合提供新的和现有的分析服务，以扩大基础的研究人员在一个新的 最先进的实验室设在IDOM内。新的实验室位置将把核心放在同一个 地板和附近的胰岛细胞生物学，功能基因组学和小鼠表型，生理学 和代谢核心，这将加强这些DRC核心之间已经密切的相互作用。集成 通过进一步发展信息学，将加强核心实验室提供的化验服务 订购、跟踪、计费和交付服务的基础设施。大量区域一体化安排的执行情况 和ELISAs在一个中央核心设施，而不是分散在整个大学的位置提供了一个 在为我们的调查人员节省设备、人力和用品方面， 由于我们增强的质量控制/质量， 保证/质量管理（QA/QC/QM）流程。我们将继续与其他国家卫生研究院合作- 赞助的核心资源和医学院在宾夕法尼亚州，以提高和扩大的数量， 为我们的研究人员提供服务，提高提供分析的效率和技术专长 服务，并继续提高我们的吞吐量和数据质量。

The Radioimmunoassay and Biomarkers Core proposes to continue offering an increasing number of high quality immunoassay services to our evolving group of Diabetes Research Center (DRC) basic, translational, and clinical scientists. Services over the last cycle have included radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and multiplex ELISA on the Luminex platform for an expanding variety of diabetes and metabolism related hormones and cytokines derived from blood, urine, and tissue samples. These assay services have proven essential for current research in the DRC and Penn's Institute for Diabetes, Obesity and Metabolism (IDOM) and will remain an integral part of the future operation and development of the Center and Institute. In the next cycle the RIA/Biomarkers Core will expand its existing services to include the development of assays on a more sensitive multiplex platform based on digital ELISA (Simoa). Simoa technology will be used to develop a novel glucagon ELISA necessary for low sample volume islet studies in rodents and in perifusion experiments, and to implement accurate multiplexing of cytokines at 1000-fold increased sensitivity required for understanding the intersection of inflammation and metabolism in rodent and human studies, and so enhance the value of assay services for DRC investigators. In addition, the Core will proactively engage in outreach to the local research community of diabetes, obesity and metabolism investigators, while enhancing the QA/QC/QM of the assay services provided. In addition, the RIA/Biomarkers Core will integrate delivery of new and existing assay services to an expanding base of investigators in a new state of the art-laboratory housed within IDOM. The new laboratory location will place the Core on the same floor and in near proximity to the Islet Cell Biology, Functional Genomics, and Mouse Phenotyping, Physiology & Metabolism Cores that will enhance the already close interactions among these DRC Cores. The integrated delivery of assay services provided by the Core will be enhanced by further development of informatics infrastructure for ordering, tracking, billing and delivery of service. The performance of a large number of RIAs and ELISAs in a central core facility rather than in scattered locations throughout the University provides a significant overall savings in equipment, personnel effort, and supplies for our investigators, while importantly allowing for the generation of results with better quality due to our enhanced quality control/quality assurance/quality management (QA/QC/QM) processes. We will continue collaborations with other NIH- sponsored core resources and the School of Medicine at Penn in order to enhance and expand the number of services available to our investigators, increase efficiency and technical expertise in the provision of assay services, and continue to improve our throughput and data quality.